Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

NCT00546936 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Presumed Ocular Histoplasmosis (POHS)

Interventions

DRUG: ranibizumab
DRUG: verteporfin

Sponsor

Barnes Retina Institute

Collaborators

[object Object]